Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting
Excerpt from the Press Release:
CAMBRIDGE, Mass., Aug. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced data on a new gene editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). The Company reported these data in an oral presentation at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers meeting, being held virtually August 18-20, 2021.
Despite major progress in achieving gene disruption, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge, SLEEK was developed enabling high knock-in efficiencies with different transgenes while also ensuring robust, transgene expression. Editas Medicine believes that SLEEK may enable the development of next generation cell therapeutics for cancer and other serious diseases.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?